How to Discontinue the Rivastigmine 13.3 mg/24h Patch
The FDA label does not provide specific tapering instructions for discontinuing rivastigmine patches; however, based on the dosing guidance, you should abruptly stop the patch rather than taper, as there is no evidence requiring gradual dose reduction when discontinuing cholinesterase inhibitors 1.
Discontinuation Approach
Direct Cessation (Recommended)
- Simply remove the current 13.3 mg/24h patch and do not apply a new one
- No gradual dose reduction is necessary when stopping treatment entirely
- The FDA label only addresses dose reduction in the context of managing adverse effects during ongoing treatment, not for permanent discontinuation 1
Key Pharmacokinetic Considerations
- Rivastigmine has a short elimination half-life of approximately 3 hours after patch removal 1
- The drug will be essentially cleared from the system within 24 hours
- This rapid clearance means there is no risk of withdrawal symptoms that would necessitate tapering
Important Clinical Context
When Dose Reduction IS Indicated (Not Discontinuation)
The FDA label specifies dose reduction only in these scenarios 1:
- If adverse effects occur during active treatment (nausea, vomiting, diarrhea, loss of appetite): discontinue for several days, then restart at the same or lower dose
- If treatment is interrupted for longer than several days: reinitiate with the lowest dose (4.6 mg/24h) and re-titrate upward
What to Expect After Stopping
- Cholinesterase inhibitor effects will reverse as the drug clears
- Cognitive and functional status may decline, returning to the trajectory expected without treatment
- The 2025 Korean guideline confirms cholinesterase inhibitors provide symptomatic benefit but do not alter disease progression 2
Common Pitfalls to Avoid
Do not confuse temporary dose reduction with permanent discontinuation. The FDA guidance about restarting at lower doses applies only when you intend to continue treatment after a brief interruption, not when permanently stopping the medication 1.
Do not attempt to "wean" by stepping down through lower patch doses (13.3 → 9.5 → 4.6 mg/24h). This is unnecessary and only prolongs the discontinuation process without clinical benefit.